Skip to main content

silevertinib

Generic: Silevertinib·Code: BDTX-1535

silevertinib: developed by 1 company · 1 clinical trial tracked.

silevertinib evidence translation

What we can confirm

What it means

Source-backed records connect silevertinib to BDTX; that link alone does not prove the drug works.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

How could silevertinib → BDTX affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence3 indications · 0 study sponsors

Related indications

Epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC) and glioblastoma (GBM); includes treatment of metastatic EGFR C797S mutation-positive NSCLC without T790M whose disease has progressed on/after a third-generation EGFR TKI; Phase 2 cohorts in 2L/3L EGFRm NSCLC with non-classical driver mutations and acquired C797S, and a 1L cohort in non-classical EGFR mutations; development for EGFR altered GBM being evaluated.Non-Small Cell Lung CancerGlioblastoma

Study sponsors

No additional listed-company sponsor is linked.

Development Pipeline (2)
CompanyPhase
Black Diamond Therapeutics, Inc. (BDTX)
Epidermal growth factor receptor mutant (EGFRm) non-small ce…
Phase 2
Black Diamond Therapeutics, Inc. (BDTX)
Non-Small Cell Lung Cancer
Phase 2
Clinical Trials (1)

A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (HGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration With PK-triggered Expansion Cohort

NCT06072586·Early Phase 1
Recruiting

Primary endpoint: Unbound BDTX-1535 Concentration in Tumor Tissue

Interventionalopen82 targetStarted 2023-10Completion 2027-122 sites · United StatesSt. Joseph's Hospital and Medical Center, Phoenix

Frequently asked questions

Who is developing silevertinib?

silevertinib is being developed by Black Diamond Therapeutics, Inc..

How many clinical trials involve silevertinib?

BioSniper tracks 1 clinical trial involving silevertinib.